THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [9.3] ID: TIP-MED-000167

Formoterol Fumarate (in Fixed-Dose Combination with Budesonide or Fluticasone)

Active Ingredient / Scientific Identity: Formoterol Fumarate • Class: Fast-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Rapid 1–3 Minute Onset)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Formoterol Fumarate (in Fixed-Dose Combination with Budesonide or Fluticasone) ([9.3] | ID: TIP-MED-000167) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/9-3-formoterol-fumarate-in-fixed-dose-combination-with-budesonide-or-fluticasone/
Generic / Entity NameFormoterol Fumarate (in Fixed-Dose Combination with Budesonide or Fluticasone) ([9.3])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassFast-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Rapid
Available Dosage FormsForacort pMDI Inhaler: Formoterol 6 mcg + Budesonide 100 mcg, 200 mcg, or 400 mcg per puff; Foracort Rotacaps
Regulatory ClassificationSchedule H Prescription Drug • NLEM 2022 Core Essential Medicine
Key Warning & Review DateMonitor closely in severe hepatic cirrhosis (reduced first-pass CYP3A4 clearance of Budesonide increases systemic steroid exp
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug • NLEM 2022 Core Essent✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Formoterol Fumarate (in Fixed-Dose Combination with Budesonide or Fluticasone) (TIP-MED-000167, Reference Code [9.3]) is classified under Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Fast-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Rapid 1–3 Minute Onset). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 09 [9.3], p. 115): Almost exclusively dispensed in India as an ICS + LABA Fixed-Dose Combination: • Formoterol + Budesonide: Foracort (Cipla—100, 200, 400), Symbicort Turbuhaler (AstraZeneca), Budamate (Lupin), Digihaler, Airtec-FB, Fomtide. • Formoterol + Fluticasone: Flohale-FB, Maxiflo. • Triple Therapy (Formoterol + Glycopyrronium/Tiotropium + Budesonide): Breztri, Zynova-G, Duova/Tioform — Strengths & Forms: Foracort pMDI Inhaler: Formoterol 6 mcg + Budesonide 100 mcg, 200 mcg, or 400 mcg per puff; Foracort Rotacaps (DPI): Formoterol 6 mcg (or 12 mcg) + Budesonide 100 mcg, 200 mcg, or 400 mcg; Respules: Formoterol 20 mcg + Budesonide 0.5 mg or 1 mg
Representative Indian Market Examples (Edition 2.7 Ch 09 [9.3], p. 115): Almost exclusively dispensed in India as an ICS + LABA Fixed-Dose Combination: • Formoterol + Budesonide: Foracort (Cipla—100, 200, 400), Symbicort Turbuhaler (AstraZeneca), Budamate (Lupin), Digihaler, Airtec-FB, Fomtide. • Formoterol + Fluticasone: Flohale-FB, Maxiflo. • Triple Therapy (Formoterol + Glycopyrronium/Tiotropium + Budesonide): Breztri, Zynova-G, Duova/Tioform — Strengths & Forms: Foracort pMDI Inhaler: Formoterol 6 mcg + Budesonide 100 mcg, 200 mcg, or 400 mcg per puff; Foracort Rotacaps (DPI): Formoterol 6 mcg (or 12 mcg) + Budesonide 100 mcg, 200 mcg, or 400 mcg; Respules: Formoterol 20 mcg + Budesonide 0.5 mg or 1 mg
Dosage Forms & Available Strengths:
Foracort pMDI Inhaler: Formoterol 6 mcg + Budesonide 100 mcg, 200 mcg, or 400 mcg per puff; Foracort Rotacaps (DPI): Formoterol 6 mcg (or 12 mcg) + Budesonide 100 mcg, 200 mcg, or 400 mcg; Respules: Formoterol 20 mcg + Budesonide 0.5 mg or 1 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Complementary dual airway action: (1) Budesonide binds intracellular Glucocorticoid Receptors (GR), translocates to the nucleus, recruits HDAC2, suppresses NF-κB/AP-1 eosinophilic cytokine transcription, and increases Beta-2 receptor transcription (preventing tolerance); (2) Formoterol is a moderately lipophilic full Beta-2 agonist with both a rapid onset (1–3 min, like Salbutamol) and a 12-hour duration of bronchodilation.

4. Therapeutic Indications & Evidence-Supported Uses

  • Maintenance and reliever therapy (MART / AIR) across GINA Steps 1–5 in Bronchial Asthma
  • Maintenance therapy in moderate-to-severe COPD with frequent exacerbations

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adults (Asthma MART): 1–2 inhalations of 200/6 mcg twice daily (or as needed for symptom relief in GINA Track 1; max 12 inhalations/day).

Administration & Meal Timing: Oral Inhalation ONLY. Never swallow DPI Rotacaps orally.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Monitor closely in severe hepatic cirrhosis (reduced first-pass CYP3A4 clearance of Budesonide increases systemic steroid exposure).
Elimination & Renal Adjustment:
No dose adjustment required.
Hepatic Impairment Considerations:
Monitor closely in severe hepatic cirrhosis (reduced first-pass CYP3A4 clearance of Budesonide increases systemic steroid exposure).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Hypersensitivity to Budesonide, Formoterol, or lactose carrier (contains milk protein traces in DPI)

Key Clinical Precautions: Monitor closely in severe hepatic cirrhosis (reduced first-pass CYP3A4 clearance of Budesonide increases systemic steroid exposure).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Oropharyngeal candidiasis (oral thrush) and dysphonia / hoarseness of voice (local steroid myopathy of vocal cords)
  • Fine tremor, palpitations, and mild hypokalaemia (from Formoterol component)
  • Pneumonia risk (slightly increased in severe COPD patients on high-dose ICS)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Strong CYP3A4 inhibitors (Ritonavir, Itraconazole, Ketoconazole, Clarithromycin): inhibit Budesonide first-pass metabolism by 4x and can precipitate iatrogenic Cushing syndrome
  • Non-selective Beta-Blockers: antagonize Formoterol bronchodilation

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • RINSE MOUTH thoroughly with water, gargle, and SPIT OUT after every inhalation to prevent oral thrush and hoarseness.
  • If using Dry Powder Capsules (Rotacaps), pierce the capsule in the Rotahaler device and inhale — NEVER swallow the capsule with water.
  • Can be used both as daily maintenance and as a rapid-relief inhaler (MART regimen) because Formoterol acts within 1–3 minutes.

Storage, Stability & Dispensing Safeguards: Store below 30°C; keep DPI capsules in moisture-tight container.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/9-3-formoterol-fumarate-in-fixed-dose-combination-with-budesonide-or-fluticasone/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.